Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer (clinicaltrials.gov) - Sep 8, 2026 - P2 | N=100 | Not yet recruiting | Sponsor: Solstice Oncology, Inc.
New P2 trial • pMMR • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor
|